Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry

Fuda, Franklin; Chen, Weina

doi:10.1007/s11899-018-0479-1

Cited by 20 publications

(13 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Theoretically, it is easy to detect T-ALL MRD since any immature T cells detected in BM or PB will be considered as MRD. T-ALL MRD backbone panels are set up to evaluate both the aberrant expression of mature T/NK-cell antigens (i.e., surface/cytoplasmic CD3, CD5, CD7, CD2, CD4, CD8, CD45, CD16, CD56) and immature markers (CD34, CD1a, TdT, CD99) (25). Based on our experience, the detection of T-ALL MRD is more challenging than B-ALL.…”

Section: Acute Lymphoblastic Leukemia (All)mentioning

confidence: 99%

Measurable Residual Disease Testing in Acute Leukemia: Technology and Clinical Significance

2022

Leukemia

View full text Add to dashboard Cite

Measurable /minimal residual disease (MRD) is the strongest independent prognostic predictor in acute leukemia. Patients with undetectable MRD or good MRD response consistently demonstrate lower risk of relapse and better survival outcomes compared with similarly treated patients with positive MRD or poor MRD response. MRD has already been used to guide riskadapted therapies in routine care of patients with acute leukemia or in clinical trials in many countries. MRD can also be used as a surveillance biomarker with potential to detect early Note to the Reader: This chapter is part of the book Leukemia (ISBN: 978-0-6453320-7-0), scheduled for publication in September 2022. The book is being published by Exon Publications,

show abstract

Section: Acute Lymphoblastic Leukemia (All)mentioning

confidence: 99%

Measurable Residual Disease Testing in Acute Leukemia: Technology and Clinical Significance

2022

Leukemia

View full text Add to dashboard Cite

show abstract

“…The presence of leukemic cells below the limit of detection by conventional cytomorphological methods is known as minimal or measurable residual disease (MRD). Persistent leukemic cells refractory to chemotherapy can be detected, identified, and measured by multiparameter flow cytometry (MFC), or molecular methods, such as quantitative polymerase chain reaction (PCR), or next-generation sequencing (NGS) techniques [ 1 , 2 , 3 , 4 , 5 , 6 ]. More sensitive methods than cytomorphology for the assessment of MRD have also redefined the state of remission in acute lymphoblastic leukemia (ALL), enabling the detection of leukemic cells in the bone marrow with less than 5% blasts and signs of hematopoietic recovery.…”

Section: Introductionmentioning

confidence: 99%

“…More sensitive methods than cytomorphology for the assessment of MRD have also redefined the state of remission in acute lymphoblastic leukemia (ALL), enabling the detection of leukemic cells in the bone marrow with less than 5% blasts and signs of hematopoietic recovery. However, patients with hematologic remission can still harbor residual leukemic cells, which could be the source of future relapse [ 1 , 2 ]. The presence of measurable residual leukemic cells after induction, as well as after consolidation chemotherapy, is a well-established prognostic factor that predicts a higher risk of relapse and shorter survival in leukemic patients regardless of their age or leukemia immunophenotype [ 7 , 8 , 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009

Pawińska-Wa̧sikowska

Bukowska-Straková

Surman

et al. 2022

Cancers

View full text Add to dashboard Cite

Measurable residual disease (MRD) is a well-known tool for the evaluation of the early response to treatment in patients with acute lymphoblastic leukemia (ALL). In respect to predicting the relapse the most informative cut-off and time point of MRD measurement during therapy were evaluated in our study. Between 1 January 2013 and 31 December 2019, multiparametric flow cytometry (MFC) MRD was measured in the bone marrow of 140 children with ALL treated according to the ALL IC-BFM2009 protocol. The MRD cut-off of 0.1% and day 33, end of induction, were the most discriminatory for all patients. Patients with negative MRD on day 15 and 33 had a higher 5-year overall survival—OS (100%) and a higher relapse-free survival—RFS rate (97.6%) than those with positive levels of MRD (≥0.01%) at both time points (77.8% and 55.6%, p = 0.002 and 0.001, respectively). Most patients with residual disease below 0.1% on day 15 exhibit hyperdiploidy or ETV6-RUNX1 in ALL cells. Measurement of MRD at early time points can be used with simplified genetic analysis to better identify low and high-risk patients, allowing personalized therapies and further improvement in outcomes in pediatric ALL.

show abstract

“…Secondly, robust, standardized methods of monitoring the treatment efficiency should be introduced into routine practice. The latter can be achieved by assessment of minimal (or measurable) residual disease (MRD) i.e., quantification of residual leukemic cells at particular time points of the treatment protocol [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia

Słota¹,

Sędek²,

Kulis³

et al. 2022

cejoi

View full text Add to dashboard Cite

Flow cytometry (FcM) is a precise and well-established tool to assess the minimal residual disease (Mrd) level in childhood acute lymphoblastic leukemia (all). it is crucial to distinguish leukemic cells from their normal counterparts; thus new markers should be evaluated, to increase the accuracy of the analysis.the expression of cd73 on blast cells was measured and compared at the day of diagnosis and at days 15 and 33 of treatment. to determine antigen expression levels, a normalized scale based on median fluorescence intensity (nMFi) was used. the study group consisted of 188 patients from the Polish Pediatric leukemia and lymphoma study group.From 177 patients with positive Mrd at day 15 of treatment, in 147 (83.1%) cases an increase of cd73 expression was observed (mean increase of +17 nMFi units). in addition, an increase of cd73 expression was noted in 26 of 31 (83.9%) patients at day 33 of treatment. in turn, a decrease of cd73 expression was observed only in 13/177 (7.3%) and 1/31 (3.2%) cases at days 15 and 33 of treatment, respectively. in 17 (9.6%) patients no change in expression of cd73 between diagnosis and day 15 of treatment was observed.in the great majority of cases the expression of cd73 is not only stable but increases during the early stages of treatment, which makes it a very useful marker to be used for Mrd monitoring in childhood B-cell precursor (BcP)-all patients.

show abstract

Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry

Cited by 20 publications

References 86 publications

Measurable Residual Disease Testing in Acute Leukemia: Technology and Clinical Significance

Measurable Residual Disease Testing in Acute Leukemia: Technology and Clinical Significance

Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009

Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia

Contact Info

Product

Resources

About